Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 8/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10450445 | 0.92 | PIN1 (0.35) | ALDH1A1KMT2AMEN1GAAMAPT | |
| SCHEMBL1288258 | 0.92 | PIN1 (0.35) | ALDH1A1KMT2AMEN1GAAMAPT | |
| SCHEMBL1288267 | 0.92 | PIN1 (0.35) | ALDH1A1KMT2AMEN1GAAMAPT | |
| SCHEMBL1688441 | 0.91 | PIN1 (0.36) | ALDH1A1KMT2AMEN1GAAPIN1 | |
| SCHEMBL10320622 | 0.89 | PIN1 (0.35) | MAPTPIN1SMN1; SMN2 | |
| SCHEMBL1288247 | 0.89 | PIN1 (0.35) | MAPTPIN1SMN1; SMN2 | |
| SCHEMBL10320667 | 0.89 | PIN1 (0.35) | MAPTPIN1SMN1; SMN2 | |
| SCHEMBL736387 | 0.89 | PIN1 (0.33) | ALDH1A1GAAPIN1SMN1; SMN2 | |
| SCHEMBL1288246 | 0.89 | PIN1 (0.35) | MAPTPIN1SMN1; SMN2 | |
| SCHEMBL10320624 | 0.89 | PIN1 (0.35) | MAPTPIN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2436685-B1 | Intermediate products for producing annulated piperazine-2-on derivatives | BOEHRINGER INGELHEIM INT (DE) | 2015-07-01 | — | — | EP | disclosed |
| EP-1819706-B1 | METHOD FOR PRODUCING ANNELATED PIPERAZIN-2-ONE DERIVATIVES AND INTERMEDIATES OF SAID METHOD | BOEHRINGER INGELHEIM INT (DE) | 2012-09-19 | — | — | EP | disclosed |
| US-RE43115-E1 | Process for the manufacture of fused piperazin-2-one derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-17 | — | — | US | disclosed |
| US-RE43115-E1 | Process for the manufacture of fused piperazin-2-one derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-17 | — | — | US | disclosed |
| US-7750152-B2 | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions and processes of making the same | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7750152-B2 | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions and processes of making the same | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7626019-B2 | Intermediate compounds for the manufacture of fused piperazin-2-one derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-01 | — | — | US | disclosed |
| US-7626019-B2 | Intermediate compounds for the manufacture of fused piperazin-2-one derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-01 | — | — | US | disclosed |
| US-20080171747-A1 | Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions | ONCOHEROES BIOSCIENCES INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080171747-A1 | Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions | ONCOHEROES BIOSCIENCES INC. | 2008-07-17 | — | — | US | disclosed |
| US-20070213529-A1 | Process for the Manufacture of fused piperazin-2-one derivatives | DURAN ADIL | 2007-09-13 | — | — | US | disclosed |
| US-20070213529-A1 | Process for the Manufacture of fused piperazin-2-one derivatives | DURAN ADIL | 2007-09-13 | — | — | US | disclosed |
| US-20070213534-A1 | Process for the Manufacture of fused piperazin-2-one derivatives | DURAN ADIL | 2007-09-13 | — | — | US | disclosed |
| US-20070213534-A1 | Process for the Manufacture of fused piperazin-2-one derivatives | DURAN ADIL | 2007-09-13 | — | — | US | disclosed |
| US-20070213531-A1 | Process for the Manufacture of fused piperazin-2-one derivatives | DURAN ADIL | 2007-09-13 | — | — | US | disclosed |
| US-20070213531-A1 | Process for the Manufacture of fused piperazin-2-one derivatives | DURAN ADIL | 2007-09-13 | — | — | US | disclosed |
| US-20070208027-A1 | Intermediate compounds for the manufacture of fused piperazin-2-one derivatives | DURAN ADIL | 2007-09-06 | — | — | US | disclosed |
| US-20070208027-A1 | Intermediate compounds for the manufacture of fused piperazin-2-one derivatives | DURAN ADIL | 2007-09-06 | — | — | US | disclosed |
| US-7238807-B2 | Hydrogenating a nitropyrimidine derivative with hydrogen in the presence of a hydrogenation catalyst, adding a copper, iron or vanadium compound to produce 7,8-dihydro-5H-pteridin-6-one derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-03 | — | — | US | disclosed |
| US-7238807-B2 | Hydrogenating a nitropyrimidine derivative with hydrogen in the presence of a hydrogenation catalyst, adding a copper, iron or vanadium compound to produce 7,8-dihydro-5H-pteridin-6-one derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213531-A1 | Process for the Manufacture of fused piperazin-2-one derivatives | DHFR, DPYD, DHPS | ALDH1A1 222/4885KMT2A 2180/4885MEN1 1745/4885 |
| US-20070213534-A1 | Process for the Manufacture of fused piperazin-2-one derivatives | DHFR, DPYD, DHPS | ALDH1A1 222/4885KMT2A 2180/4885MEN1 1745/4885 |
| US-20080171747-A1 | Intermediate Compounds for making Dihydropteridinones Useful as Pharmaceutical Compositions | QDPR, DHPS, DHODH | ALDH1A1 759/4885KMT2A 4704/4885MEN1 690/4885 |
| US-20070208027-A1 | Intermediate compounds for the manufacture of fused piperazin-2-one derivatives | DHFR, DPYD, DHPS | ALDH1A1 222/4885KMT2A 2271/4885MEN1 1207/4885 |
| US-20070213529-A1 | Process for the Manufacture of fused piperazin-2-one derivatives | DHFR, DPYD, DHPS | ALDH1A1 222/4885KMT2A 2180/4885MEN1 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.